UK performance nutrition brand launches long-term investment in Japanese endurance sport.

TOKYO, July 1, 2026 /PRNewswire/ — Science in Sport (SiS), the global performance nutrition brand trusted by elite athletes and teams around the world, has announced its launch in Japan.

Home to more than 70 million sports participants and 8 million runners, Japan has a rich and deeply embedded endurance culture. From major marathons to the tradition of Ekiden relay racing, endurance sport occupies a special place within Japanese society and reflects values of discipline, teamwork, perseverance and continual improvement.

For Science in Sport, the opportunity extends beyond market size. The company sees a strong alignment between Japanese sporting culture and its own mission to unlock human performance in sport through science-led performance nutrition.

The launch establishes Japan as Science in Sport’s priority market in Asia and builds on the company’s successful expansion across the region. The investment includes a dedicated Japanese direct-to-consumer platform, local expertise, strategic commercial partnerships and Japanese-language educational content designed to help athletes better understand and apply performance nutrition.

As part of this commitment, Science in Sport has partnered with RunNet, Japan’s largest running platform, to create athlete storytelling, educational content and performance nutrition guidance tailored specifically for Japanese runners.

The company has also appointed Japanese endurance athletes Kazuto Iizawa and Takako Takamura as ambassadors for the brand, helping to connect global sports science with the realities of training and competing in Japan.

Science sits at the heart of the company’s approach. Science in Sport works with one of the most extensive networks of sports nutrition experts in the industry through its Scientific Advisory Panel, comprising leading academics, researchers and practitioners from world-class universities and elite sport programmes.

This expertise is complemented by the company’s Elite Performance Advisory Panel, which includes Sir Chris Hoy, Dame Jessica Ennis-Hill, Dame Laura Kenny and Eilish McColgan. The panels help guide research priorities, product innovation and athlete education, ensuring that Science in Sport continues to translate elite performance knowledge into practical solutions for athletes at every level.

Science in Sport recently became title partner of the UK Ekiden. Ekiden is one of Japan’s most cherished sporting traditions and embodies the values of both endurance sport and the Science in Sport philosophy: teamwork, commitment, trust and collective achievement.

McColgan commented, “The Japan launch is a pivotal moment for Science in Sport. Having recently taken part in both the Marugame Half Marathon and the UK Ekiden, I experienced firsthand the enthusiasm and commitment to endurance sport that are deeply embedded in Japanese culture.”

Dan Lampard, Chief Operating Officer at Science in Sport, said:

“Japan is one of the most exciting performance nutrition markets in the world, but what attracted us most was not simply its size. It is the country’s unique endurance culture, its passion for continual improvement and the respect athletes place on quality, preparation and performance.

“For more than 30 years we have helped athletes fuel some of the world’s biggest sporting achievements by translating sports science into products that work in the real world. We believe Japanese athletes are increasingly looking for trusted, evidence-based nutrition solutions and we see a strong alignment between what they value and what Science in Sport stands for.

“We want to become a meaningful part of the endurance community through education, local partnerships, athlete support and long-term investment in the market.

“This is the beginning of a long-term commitment to Japanese sport and we are excited to help athletes across running, cycling, fitness and endurance disciplines unlock their full potential.”

Kazuto Iizawa, current 1500m Japan and Asian champion, 2025 Tokyo World Championships 1500m Japan National Team, commented:

“After using SiS myself, I’ve really come to appreciate how practical and effective it is for supporting performance. The products are easy to take and fit seamlessly into my everyday training. I’m excited to see SiS officially expand into Japan, making world-class sports nutrition more accessible to athletes and runners across the country.”

Takako Takamura, ACG (Nike) athlete, 2025 mountain and trail running World Championships Japan national team, added: 

“What I appreciate about SiS is not only how easy the products are to use, but also the opportunity to learn about world-class sports nutrition. From pre-training preparation and fuelling during exercise to recovery, the product range supports every stage of performance.

I also value the opportunity to learn from sports nutritionists, who share the latest research and practical insights, including nutrition and conditioning for female athletes. Beyond the products themselves, this knowledge and support are invaluable for improving performance.

I’m excited that more female runners in Japan will have the opportunity to experience SiS.”

Science in Sport’s activities in Japan will be led by a dedicated local team, ensuring cultural relevance and effective market execution while maintaining the company’s standards for quality, compliance and athlete welfare.

Photo – https://laotiantimes.com/wp-content/uploads/2026/07/science_in_sport_1.jpg
Photo – https://laotiantimes.com/wp-content/uploads/2026/07/science_in_sport_2.jpg

The collaboration leverages Colossal’s marsupial de-extinction and conservation biotechnology platform to save the Tasmanian devil from a contagious cancer that has driven 80% population declines across Tasmania

DALLAS and HOBART, Australia, July 1, 2026 /PRNewswire/ — The Colossal Foundation, the nonprofit conservation arm of Colossal Biosciences, today announced a new partnership with the University of Tasmania to support efforts to combat Devil facial tumour disease (DFTD), a fatal transmissible cancer that has devastated wild Tasmanian devil populations and threatens the iconic marsupial with extinction.

Under the partnership, the Colossal Foundation will support the establishment of a fat-tailed dunnart research colony at the Menzies Institute for Medical Research at the University of Tasmanian, Hobart. The two teams will also collaborate on gene-editing capabilities to advance DFTD vaccine testing and explore the long-term potential of heritable resistance to transmissible cancers in dasyurid marsupials which includes the Tasmanian devils. The collaboration extends the marsupial biotechnology platform Colossal has built through its thylacine de-extinction program, and joins a growing portfolio of marsupial conservation initiatives in Australia that includes a world-first demonstration of engineered cane toad toxin resistance for the endangered northern quoll.

“Devil facial tumour disease is one of the most devastating wildlife diseases on Earth. This contagious cancer is pushing an iconic marsupial toward collapse, with consequences for the ecology of an entire island,” said Matt James, Executive Director of the Colossal Foundation. “Andy Flies and his team at the University of Tasmania have built the most advanced DFTD vaccine pipeline in existence. By combining that work with Colossal’s marsupial husbandry, reproductive science, and gene-editing platform, we have a real opportunity to accelerate this effort and give the Tasmanian devil a fighting chance.”

A CONSERVATION CRISIS WITHOUT MODERN PRECEDENT

The Tasmanian devil (Sarcophilus harrisii), the world’s largest living carnivorous marsupial, is threatened by two independent transmissible cancers: Devil facial tumour 1 (DFT1), was discovered in 1996 and has since spread across most of the species’ range. The second, DFT2, was identified in 2014 in southern Tasmania and is still emerging. Both cancers cause large tumours around the mouth and face that can prevent devils from eating, and both are nearly 100% fatal. The disease is transmitted directly between devils through biting, a behaviour central to feeding and mating, making it almost impossible to control by conventional means.

Wild devil populations have collapsed by approximately 80% since DFTD’s emergence. As Tasmania’s apex scavenger and predator, devils play an important ecological role, helping suppress feral cats and reducing pressure on smaller native species. Their decline has had cascading effects across Tasmania’s ecosystems, making DFTD not only a species-level crisis, but a much broader conservation problem.

A TWO-PART STRATEGY: VACCINES + GENE EDITING

The University of Tasmania Wild Immunology Group, led by Associate Professor Andrew Flies, Ph.D., has been developing a two-pronged strategy to help the devil immune system recognize and fight DFTD. The first prong is an advanced vaccine program. Flies’s team has developed a field-ready oral bait vaccine designed to train the devil immune system to recognize and destroy DFT1 and DFT2 cells, and that could one day protect wild devils across the Tasmanian landscape without requiring every animal having to be trapped and injected.

The second prong is a gene-editing strategy centered on LZTR1, a gene that is connected to cancer-relevant pathways in other species, and is hypothesized to play an important role in the origin and biology of devil facial tumors. Tasmanian devils carry two unusual amino-acid substitutions in LZTR1 that are not found in other mammals, and the “shattering” of one copy of the LZTR1 gene has been identified as a potential driver event in the origin of DFT1. The partnership between Colossal and University of Tasmania will explore whether targeted editing of the devil-specific LZTR1 mutations to match the ancestral mammalian sequence could reduce the underlying susceptibility of devils to these transmissible cancers.

Under the partnership, the LZTR1 gene-editing work will advance on two complementary tracks. The Colossal Australia team in Melbourne will edit LZTR1 in fat-tailed dunnart induced pluripotent stem cells (iPSCs), while the Anuk Kruawan, Ph.D. at University of Tasmania will edit LZTR1 in devil cell lines. Results from these complementary approaches will determine whether LZTR1 biology is relevant to future disease-resilience strategies

“We’ve spent years developing a vaccine designed to train the devil immune system to fight these cancers but progress is slow due to the challenges of working with an endangered species and having a lack of marsupial research tools,” said Associate Professor Andrew Flies at Menzies Institute for Medical Research, University of Tasmania. “We won’t know if the vaccine is effective until we perform field trials with naturally-infected devils. However, before we can start field trials, we need to make sure the vaccine is safe and induces a strong immune response in devils and other species that could eat a vaccine bait. Partnering with the Colossal Foundation can significantly accelerate our vaccine work, and allow us to explore a gene-editing strategy in parallel that could enhance the vaccine and make devils more resistant to DFTD.”

A DE-EXTINCTION PLATFORM, DEPLOYED FOR DEVILS

Testing a new vaccine and gene-editing approach in a marsupial system requires specialised facilities, careful adherence to regulatory requirements, and biologically appropriate models. The fat-tailed dunnart (Sminthopsis crassicaudata), a small, mouse-sized dasyurid that is a close evolutionary relative of both the Tasmanian devil and the thylacine, provides that bridge.

The Colossal Foundation is supporting the University in establishing a dedicated dunnart colony in the Menzies Institute for Medical Research facility in Hobart, with Colossal Australia’s animal-care team hosting University of Tasmania veterinarians and animal services staff to transfer husbandry, breeding, and welfare protocols developed through years of dunnart colony management. Once operational, the Hobart colony will allow vaccine safety and immunogenicity trials to be run in a biologically relevant marsupial model. This is a critical regulatory and scientific step toward devil trials and eventual field deployment.

Colossal’s work has made the fat-tailed dunnart one of the most important marsupial models in the world. Through the thylacine de-extinction program, Colossal and the University of Melbourne have advanced dunnart biology through the development of a complete genome, cell lines, induced pluripotent stem cells (iPSCs), genome editing, assisted reproductive technologies, and husbandry systems. Those same tools are now being applied to conservation challenges facing living species, including the Colossal Foundation’s northern quoll project, which uses the dunnart as a closely related model to test gene-editing strategies for cane toad toxin resistance.

“The dunnart has become the foundation of Colossal’s marsupial platform,” said Andrew Pask, Chief Biology Officer at Colossal Biosciences. “To build the thylacine program, we had to develop tools for marsupial cell culture, gene editing, reproductive biology, and husbandry that simply did not exist at this level before. Now those tools can be applied to living species. Bringing that platform into the Tasmanian devil cancer effort with the University of Tasmania is a powerful example of how de-extinction science can deliver immediate conservation value for living species.”

“This partnership reflects exactly why Colossal exists,” said Ben Lamm, Co-Founder and CEO of Colossal. “Our de-extinction programs are fueling the development of entirely new biological tools and platforms. In Australia, the work we are doing to bring back the thylacine has already helped establish the dunnart as a powerful model for marsupial genomics and reproductive science. We’re now deploying those same technologies against one of the most devastating wildlife diseases on Earth. This is what the conservation power of de-extinction looks like.”

A REGIONAL ECOSYSTEM OF CONSERVATION PARTNERS

The DFTD partnership joins a growing network of Tasmanian and Australian conservation organizations engaged with Colossal’s marsupial work. Bonorong Wildlife Sanctuary, Tasmania’s leading wildlife rescue, rehabilitation, and conservation organizations, expressed strong interest in the project and in its potential relevance for Tasmanian devil conservation. Bonorong’s work on the front lines of wildlife care gives it a direct understanding of the stakes of devil recovery and the importance of developing new tools to support the species.

“For nearly thirty years, we have watched DFTD mercilessly take countless devils from the Tasmanian landscape. At Bonorong we’ve cared for hundreds of Devils as this horrific plague rages on,” said Greg Irons, Director of Bonorong Wildlife Sanctuary. “Anything that gives our devils a real path back deserves our full support.”

The partnership also has the backing of the Tasmania Thylacine Advisory Committee (TTAC), a group of Tasmanian community, conservation, business, and local leaders assembled to guide Colossal’s work in Tasmania.

“The Tasmanian devil is one of the most iconic endangered species on Earth — recognised globally, but with deep roots in Tasmania’s wild landscapes and identity,” said Michelle Dracoulis, Mayor of the Derwent Valley Council and Chair of the TTAC. “What Associate Professor Andrew Flies and his team have built in Hobart is genuinely world-class. Seeing that work strengthened through the support of the Colossal Foundation gives real hope for the future of the species, and demonstrates how emerging technologies can be applied directly to urgent conservation challenges. The TTAC is pleased to support this partnership and the opportunities it creates for globally significant conservation science aimed at protecting Tasmania’s devils.”

Beyond Tasmania, the new collaboration complements Colossal’s broader Australian conservation partners network. Aussie Ark, one of Australia’s foremost private conservation organizations, is a leader in Tasmanian devil insurance population breeding on the mainland, and Zoos Victoria has a long-standing partnership with Colossal on the conservation of the Critically Endangered Victorian Grassland Earless Dragon.

“Every major conservation challenge teaches us something different,” said Andrew Pask, Chief Biology Officer at Colossal. “With the thylacine, we are building the tools to reverse extinction. With the northern quoll, we are applying those tools for resilience to invasive-species. With the Tasmanian devil, we are now applying them to infectious cancer, one of the most extraordinary disease problems in vertebrates. That is the future of disruptive conservation: build the platform once, then move it quickly and responsibly wherever biodiversity needs it most.”

ABOUT THE COLOSSAL FOUNDATION

The Colossal Foundation is a 501(c)(3) dedicated to supporting the use of cutting-edge technologies to conservation efforts globally to help prevent extinction of keystone species. The organization deploys cutting-edge de-extinction technologies and support to empower partners in the field to reverse the extinction crisis. www.ColossalFoundation.org.

ABOUT THE UNIVERSITY OF TASMANIA AND THE MENZIES INSTITUTE FOR MEDICAL RESEARCH

The University of Tasmania is Australia’s fourth-oldest university and the only university based in Tasmania, with a deep institutional commitment to research that addresses the unique conservation, health, and environmental challenges of its island state. The Menzies Institute for Medical Research, University of Tasmania’s flagship medical research institute, is one of Australia’s leading health and medical research institutes. The Menzies Wild Immunology Group, led by Associate Professor Andrew Flies, focuses on wildlife immunology and vaccine development, including efforts to protect Tasmanian devils from devil facial tumour disease. Learn more at menzies.utas.edu.au.

ABOUT BONORONG WILDLIFE SANCTUARY

Established in 1981, Bonronog Wildlife Sanctuary is an iconic enterprise committed to the conservation of native species, through wildlife rescue and rehabilitation, education, and experiences that connect people and wildlife. Learn more at bonorong.com.au.

WEBSITE & SOCIALS

Websites: www.colossal.com

Instagram: https://www.instagram.com/colossal/

YouTube: https://www.youtube.com/@colossal

Twitter: https://x.com/colossal

LinkedIn: https://www.linkedin.com/company/colossal/

Facebook: https://www.facebook.com/itiscolossal

TikTok: https://www.tiktok.com/@colossal

BlueSky: https://bsky.app/profile/itiscolossal.bsky.social

Logo – https://laotiantimes.com/wp-content/uploads/2026/07/colossal_foundation_logo.jpg

Share trading platform, Webull Australia, is partnering with Qantas Frequent Flyer, the nation’s largest airline loyalty program, to give Australian clients a new way to earn Qantas Points.

SYDNEY, July 1, 2026 /PRNewswire/ — Webull Securities (Australia) Pty Ltd (“Webull Australia”), a subsidiary of Webull Corporation (NASDAQ: BULL), the owner of the Webull trading platform, today announced a new partnership with Qantas Frequent Flyer that will enable new and existing eligible clients to earn Qantas Points. This offer gives clients three ways to earn Qantas Points via Webull Australia, which include:

• Welcome Offer | Earn 1,000 bonus Qantas Points: New clients who open a Webull account, make an initial deposit or share transfer of AUD$500 or more and maintain the deposit for 30 calendar days, will receive 12 months of complimentary 24-Hour Live US Market Data (Level 2) and 1,000 bonus Qantas Points.
• Deposit & Transfer Offer | Earn up to 100,000 bonus Qantas Points:

New clients who reach an eligible balance of AUD$2,000 or more will earn 1 Qantas Point per AUD$1, capped at 100,000 points. Offer available from 1 July 2026 to 30 September 2026. Points are awarded in four instalments when you retain your balance until 31 July 2027.

• Trade Offer | Earn up to 2,000 Qantas Points per month: Existing clients who execute buy orders across available international markets, including U.S. Stocks, ETFs, Hong Kong Stocks, and China A shares will earn up to 200 Qantas Points per trade, up to 2,000 points per month per individual.     

Respective Terms and Conditions Apply.

“We want to give investors another reason to choose Webull, and partnering with the largest national airline loyalty program in Australia, Qantas Frequent Flyer, helps us do just that,” said Rob Talevski, CEO of Webull Australia. “In addition, rewarding our clients for building their portfolios and trading in global markets felt like a natural addition to our overall offering. This partnership gives clients a new and compelling way to keep earning Qantas Points through an activity they’re already doing.”

Webull is a CHESS-sponsored broker, and one of the few global share trading platforms to hold both ASX and Cboe Australia market participant status. The platform combines zero-brokerage investing across multiple markets, 24/5 access to US markets, and real-time market data, an AI powered assistant, and advanced investing tools to support clients at every stage of their journey.

###

Media Enquiries
Cognito for Webull: webull@cognito.com

About Webull Australia

Webull Securities (Australia) Pty. Ltd. is a financial services provider, holding an Australian Financial Services Licence (AFSL 536980) and regulated by the Australian Securities and Investments Commission (ASIC). As a trading participant of both the Australian Securities Exchange (ASX) and Cboe Australia (Cboe), and a principal member of the Stockbrokers and Investment Advisers Association, Webull strives to ensure the highest standards of service and security. Learn more at www.webull.com.au.

About Webull Corporation

Webull Corporation (NASDAQ: BULL) owns and operates Webull, a digital investment platform built on next-generation global infrastructure. Through its global network of licensed brokerages, Webull offers investment services in 16 markets across North America, Asia Pacific, Europe, Africa, and Latin America. Webull serves more than 27 million registered users globally, providing retail investors with 24/7 access to global financial markets. Users can put investment strategies to work by trading global stocks, ETFs, options, futures, fractional shares, and digital assets through Webull’s trading platform, which seamlessly integrates market data and information, its user community, and investor education resources. Learn more at www.webullcorp.com.

About Qantas Frequent Flyer

Launched in 1987, the Qantas Frequent Flyer program is one of Australia’s largest loyalty programs with over 17 million members. Members can earn Qantas Points flying with Qantas, Jetstar and dozens of partner airlines, as well as through everyday spending with 500 program partners across financial services, retail shopping, car hire, insurance and more.

Members can also earn Status Credits to progress through the program’s five membership tiers, with each tier unlocking an array of exclusive travel benefits.

PHUKET, Thailand, July 1, 2026 /PRNewswire/ — Renaissance Phuket Resort & Spa has unveiled a new all-inclusive package in Phuket, combining newly renovated accommodations with unlimited breakfast, lunch, dinner, and beverages. The package invites travelers to experience more of Phuket through award-winning dining, authentic local culture, wellness, and family-friendly activities—all included in one seamless holiday.

Recently recognized at the 2026 Haute Grandeur Global Excellence Awards and with the Tripadvisor Travelers’ Choice Best of the Best Award, the resort combines world-class hospitality with meaningful destination experiences on the pristine shores of Mai Khao Beach.

More Than an All-Inclusive Stay

Unlike traditional all-inclusive resorts, Renaissance Phuket Resort & Spa encourages guests to explore the destination through local flavors, cultural discoveries, and signature experiences inspired by Phuket.

Guests can enjoy dining across the resort’s restaurants and bars, from authentic Southern Thai cuisine at Takieng and beachfront dining at Sand Box Beachfront Bar & Eatery to locally inspired breakfasts at Loca Vore, handcrafted coffee at Doppio, and cocktails at The Lounge. The experience will soon expand with Yunami, a new coastal izakaya inspired by seaside Japan, opening in late July.

Discover Phuket Beyond the Beach

Guests can discover Phuket through local markets, Thai cooking experiences, cultural landmarks, and charming neighborhoods. Through the resort’s Navigator program and Good Travel with Marriott Bonvoy, including Market-to-Table experiences, guests can connect more deeply with the destination, local communities, and Phuket’s culinary heritage.

Wellness, Family Time and Relaxation

Whether enjoying Quan Spa, daily wellness activities, cycling around the destination, or creating memories with Kids Yoga, fish feeding, arts and crafts, and the signature Marshmallow BBQ, every stay is designed to bring families, couples, and friends closer together.

Everything Included. Nothing Ordinary.

The Ultimate All-Inclusive Package includes a daily buffet breakfast, unlimited lunch and dinner, and unlimited beverages across the resort’s six restaurants and bars. Guests also enjoy full access to the resort’s facilities, including the beachfront swimming pool, Mai Khao Beach, Discovery Hour, a 24-hour fitness centre, and a variety of daily activities for both adults and children.

*Package inclusions are subject to terms and conditions.

Discover more about Renaissance Phuket Resort & Spa at www.renaissancephuket.com

Stay connected:
Facebook: Renaissance Phuket Resort & Spa
Instagram: @renaissancephuket

In the news release, NYSE Content Update: Klaviyo Launches AI Agents to Elevate Consumer Brands, issued 30-Jun-2026 by New York Stock Exchange over PR Newswire, the video has been updated.

NYSE Content Update: Klaviyo Launches AI Agents to Elevate Consumer Brands

NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, June 30, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Ashley Mastronardi delivers the pre-market update on June 30th

• The major averages look to build on gains after the Dow closed above 52,000 for the first time.
  • Global X NYSE 100 ETF component Alphabet gained 4.8% in its first day of trade on the Dow.
• Klaviyo (NYSE: KVYO) unveils a pair of AI agents that will work together to boost revenue for consumer brands.
  • The company’s AI marketing agent, Composer, moves to public beta while customer agent receives series of advancements.
  • CMO Jamie Domenici will join NYSE Live to explain how this is designed to change the future of customer experiences.
• The Zerohash Onchain Brokerage Summit takes place at the NYSE today, bringing together leaders to discuss the future of digital assets and tokenization.

Opening Bell
JPMorgan Chase (NYSE: JPM) highlights their ongoing commitment to championing inclusion and belonging

Closing Bell
Smithsonian’s National Air and Space Museum celebrates its 50^th anniversary

For market insights, IPO activity, and today’s opening bell, download the NYSE TV App: TV.NYSE.com

NYSE_Deutsche_Bank

Scientists can now design potent antibiotics and rapidly prioritise vaccine targets through Claude Science, thanks to integration with Basecamp Research’s EDEN models.

LONDON and CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ — Basecamp Research today announced that its antibiotic design and vaccine target prediction EDEN models are now available through Claude, including Claude Science, Anthropic’s AI workbench for life sciences research. This allows researchers to generate and prioritise therapeutic candidates through a conversational interface in a matter of minutes.

By combining Claude’s reasoning with EDEN’s biological design capabilities, researchers can now go straight from a target to a shortlist of high-performing antibiotic or vaccine candidates. This capability is available in Claude.ai, Claude Desktop, Claude Mobile, Claude Code, Cowork, and Claude Science through Anthropic’s connectors directory.

The world needs new antibiotics

Drug-resistant infections play a role in nearly 5 million deaths per year, but the pharmaceutical industry has largely retreated from antibiotic development. New antibiotics are badly needed, particularly for the pathogens spreading fastest in lower-income countries where last-resort drugs are hardest to access.

“Microbes have been producing antibiotics and evolving resistance to each other for billions of years,” said Glen Gowers, Co-founder and CEO of Basecamp Research. “EDEN learned from that history, and now, through Claude, researchers all over the world can design successful new antibiotics in minutes, not years.”

In collaboration with University of Pennsylvania researchers, Basecamp Research demonstrated that 97% of the antibiotic peptides designed by EDEN are active against World Health Organisation (WHO)  priority pathogens when tested in the lab. Fleming Prize winner and Presidential Associate Professor César de la Fuente led the work by UPenn’s Machine Biology Group.

One candidate, EDEN-7, was tested in mice infected with multidrug-resistant Acinetobacter baumannii – a pathogen associated with hospital outbreaks worldwide – and showed efficacy in the same range as a last-line antibiotic, despite being generated zero-shot, meaning the model produced it without subsequent optimization or iterative engineering.

“This collaboration shows how frontier biological foundation models can be paired with rigorous experimental validation to accelerate antibiotic discovery,” de la Fuente said. “Antimicrobial resistance is one of the greatest existential threats facing humanity and collaborations like this between academia and industry are critical.”

Finding vaccine targets in minutes

Developing a vaccine against an emerging pathogen is a race against time. Which part of the pathogen to target is often determined empirically, which can take months of laboratory work.  This delay often costs lives.

EDEN’s vaccine design model identifies which proteins are most likely to trigger a protective immune response, outperforming comparable genomic foundation models. By integrating it into Claude, researchers can describe a problem in plain language and have Claude run a prioritisation workflow against the pathogen’s genetic sequence. This can reduce several weeks of research per pathogen into a single conversation.

A growing collaboration

“The antibiotic crisis and the need for new vaccines are two of the most important public health challenges of our time,” said Jonah Cool, Head of Life Sciences Partnerships and Deployment at Anthropic. “Making EDEN available through Claude Science gives researchers a new way to explore and prioritise treatments for some of the most dangerous pathogens on Earth.”

Built on the world’s largest biological dataset

Most biological AI models are trained on a narrow set of well-studied organisms – the ones scientists have already catalogued. In contrast, EDEN is trained on BaseData, the largest, fastest-growing and most information-rich biological database on Earth.

To build it, Basecamp Research has run expeditions to over 200 locations across more than 30 countries, sampling the places life is strangest and least understood, including thermal springs, deep-sea sediment, polar ice, remote high-altitude plateaus. In the process, it has documented more than a million species new to science. The result is over 10 billion new genes and roughly ten times the content of every public database combined.

Basecamp Research aims to scale BaseData 100-fold over the next two years through the Trillion Gene Atlas, a partnership with Anthropic, NVIDIA, PacBio and Ultima Genomics designed to generate genomic data at the trillion-gene scale for AI-driven drug discovery.

Diversity is what drives EDEN’s performance across a wide range of tasks. Every sample is collected under informed-consent and benefit-sharing agreements so that the countries and communities who steward this biodiversity share in the value it creates, with each sequence traceable to one of hundreds of country-specific permits. This allows a portion of revenue to be fed back to the country and community where the data was originally sourced, setting a standard of data provenance that the rest of the field has yet to match.

About Basecamp Research 
Basecamp Research is dedicated to solving major challenges in healthcare and life sciences by exploring Beyond Known Biology™. The company trains frontier AI models on BaseData, the world’s largest biological dataset, collected through partnerships with more than 200 organisations across more than 30 countries. Basecamp Research is developing a pipeline of therapeutics and works with commercial and academic partners worldwide to accelerate therapeutic discovery and development.

BaseData™, Beyond Known Biology™, EDEN-GLM™ and aiPGI™ are trademarks and technologies of Basecamp Research.

Acquisition expands global AI deployment platform by adding a profitable enterprise software business with recurring revenue.

WILMINGTON, Del. and MUNICH, July 1, 2026 /PRNewswire/ — Brand Engagement Network, Inc. (NASDAQ: BNAI) (“BEN” or the “Company”), an enterprise AI software company, today completed its acquisition of Cataneo GmbH (“Cataneo”), a profitable enterprise software provider that generated more than €8.6 million in 2025 revenue and whose platform manages more than €6 billion in annual advertising inventory across more than 1,000 media brands and 200+ broadcast and digital channels.

Cataneo, a Munich-based provider of enterprise software for advertising operations and infrastructure, operates the MYDAS platform, which supports advertising sales, scheduling, traffic, content management, monetization, analytics, CRM integration, and real-time reporting for broadcasters and media organizations worldwide. The acquisition provides BEN with an established enterprise software platform, long-standing customer relationships, and mission-critical workflows where its AI technologies can be integrated and deployed.

The acquisition of Cataneo enhances BEN’s ability to embed enterprise AI into real-world operational environments across the media and advertising ecosystem, strengthening its position as an enterprise AI software provider.

The strategic value of the acquisition is twofold. First, BEN intends to integrate its proprietary Engagement Language Model (ELM™) and enterprise AI technologies into the Cataneo platform to enhance advertising operations, audience intelligence, workflow automation, forecasting, and operational decision-making. Second, Cataneo provides an established commercial platform through which BEN can deploy AI-powered enterprise solutions to existing customers while expanding into additional industries over time.

Scale at a Glance

• €6B+ in annual advertising inventory managed
• 1,000+ global media brands
• 200+ broadcast and digital channels
• Operations spanning four continents
• Established global enterprise customer base
• Proven enterprise software platform with recurring revenue and strong customer retention
• Immediate infrastructure for deployment of BEN’s enterprise AI technologies

Cataneo Financial Highlights

• 2025 Revenue: €8,636,708
• First Half 2026 Estimated Revenue: €4,186,975

As part of the transaction, Cataneo Co-Founder Christian Unterseer has joined BEN’s Board of Directors. Integration efforts are now underway, with both organizations continuing to support customers without disruption.

Leadership Perspectives

Tyler Luck, Co-Founder and Chief Executive Officer, Brand Engagement Network

 “AI is becoming the engagement layer between brands and consumers. As enterprise AI and media infrastructure come together, we’re moving toward a world of real-time, one-to-one engagement across connected environments. Instead of one-way messaging, brands can interact directly, and those interactions become measurable, intelligent, and actionable. This acquisition expands that vision by combining BEN’s enterprise AI platform with Cataneo’s established global software business, including its long-standing customer relationships and mission-critical enterprise workflows.”

Renato Rocha Pinto, Chief Executive Officer, Cataneo GmbH

“For more than two decades, Cataneo has built a trusted enterprise platform supporting leading media organizations around the world. Joining BEN enables us to pair that operational expertise with enterprise AI while continuing to deliver the reliability, continuity, and service our customers expect.”

Christian Unterseer, Co-Founder, Cataneo GmbH and Director, Brand Engagement Network

“What impressed us most about BEN was its practical vision for enterprise AI. By combining Cataneo’s operational expertise with BEN’s AI platform, we believe we can simplify complex workflows, improve decision-making, and create measurable customer value across multiple industries.”

Together, BEN and Cataneo combine enterprise AI with proven software infrastructure, creating a broader operating foundation for intelligent automation, customer engagement, and operational excellence across industries.

Transaction Details
The acquisition was completed on June 30, 2026. Additional details regarding the transaction are included in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 30, 2026.

About Cataneo GmbH
Cataneo GmbH is a global provider of enterprise software for advertising sales, scheduling, traffic, and content management across linear, digital, and on-demand media. Its MYDAS platform provides end-to-end media management, monetization, analytics, CRM integration, and real-time reporting solutions for broadcasters and media organizations worldwide. For more information, visit www.cataneo.com.

About Brand Engagement Network
Brand Engagement Network, Inc. (NASDAQ: BNAI) is an enterprise AI software company that enables organizations to connect engagement to execution through secure, intelligent conversational AI. Powered by its proprietary Engagement Language Model (ELM™), BEN helps organizations automate workflows, improve customer experiences, and drive operational intelligence across healthcare, hospitality, mobility, government, media, retail, and other industries.

The acquisition of Cataneo expands BEN’s global deployment infrastructure by adding a proven enterprise software platform, established customer relationships, and international distribution capabilities, creating new opportunities to deploy BEN’s enterprise AI at scale while reinforcing the Company’s position as an enterprise AI software provider.  For more information, visit www.brandengagementnetwork.com.

Media Contact
Amy Rouyer
amy@beninc.ai

Investor Relations
investors@beninc.ai

Logo – https://laotiantimes.com/wp-content/uploads/2026/07/brand_engagement_network_logo.jpg